Zacks Investment Research lowered shares of OncoCyte Corp (NYSEAMERICAN:OCX) from a hold rating to a sell rating in a report published on Saturday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, ValuEngine lowered OncoCyte Corp from a hold rating to a sell rating in a report on Friday, July 28th.
Shares of OncoCyte Corp (NYSEAMERICAN OCX) opened at $4.30 on Friday. OncoCyte Corp has a fifty-two week low of $3.60 and a fifty-two week high of $7.95.
An institutional investor recently raised its position in OncoCyte Corp stock. Broadwood Capital Inc. grew its holdings in OncoCyte Corp (NYSEAMERICAN:OCX) by 17.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the period. OncoCyte Corp comprises about 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th biggest position. Broadwood Capital Inc. owned about 11.48% of OncoCyte Corp worth $27,155,000 at the end of the most recent quarter.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.